Bronte Capital Management Pty Ltd. Has $5.11 Million Stock Holdings in Bath & Body Works, Inc. $BBWI

Key Points

• Bronte Capital increased its stake in Bath & Body Works by 121.8% in Q4 to 254,611 shares, worth $5.11 million and representing about 0.6% of Bronte’s portfolio (the firm's 22nd largest holding).
• Bath & Body Works beat Q4 estimates with $2.05 EPS (vs. $1.77 expected) and $2.72 billion in revenue, and issued Q1 2026 guidance of $0.240–0.300 EPS and FY 2026 guidance of $2.400–2.650 EPS.
• The stock yields about 4.4% (quarterly dividend $0.20), trades at a P/E of 5.84 with a $3.7 billion market cap, and carries a MarketBeat consensus rating of “Hold” with a $23 price target.

Bronte Capital Management Pty Ltd. lifted its holdings in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 121.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 254,611 shares of the company's stock after buying an additional 139,810 shares during the period. Bath & Body Works comprises approximately 0.6% of Bronte Capital Management Pty Ltd.'s portfolio, making the stock its 22nd biggest position. Bronte Capital Management Pty Ltd. owned about 0.12% of Bath & Body Works worth $5,113,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Horizon Corp acquired a new stake in shares of Bath & Body Works in the third quarter worth $29,000. Geneos Wealth Management Inc. boosted its position in Bath & Body Works by 217.7% during the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company's stock valued at $35,000 after purchasing an additional 801 shares during the last quarter. Danske Bank A S acquired a new stake in Bath & Body Works during the third quarter valued at $39,000. Activest Wealth Management acquired a new stake in Bath & Body Works during the fourth quarter valued at $32,000. Finally, Advisory Services Network LLC acquired a new stake in Bath & Body Works during the third quarter valued at $48,000. Institutional investors and hedge funds own 95.14% of the company's stock.

Bath & Body Works Price Performance

NYSE BBWI opened at $18.38 on Wednesday. Bath & Body Works, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $34.66. The stock's 50-day moving average is $19.77 and its two-hundred day moving average is $21.05. The firm has a market cap of $3.70 billion, a P/E ratio of 5.84, a price-to-earnings-growth ratio of 1.86 and a beta of 1.43.

Bath & Body Works (NYSE:BBWI - Get Free Report) last posted its earnings results on Wednesday, March 4th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.28. Bath & Body Works had a negative return on equity of 45.60% and a net margin of 8.90%.The company had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same period last year, the company earned $2.09 earnings per share. The business's revenue was down 2.3% compared to the same quarter last year. Bath & Body Works has set its Q1 2026 guidance at 0.240-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. On average, equities analysts expect that Bath & Body Works, Inc. will post 2.6 EPS for the current year.

Bath & Body Works Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Friday, February 20th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.4%. The ex-dividend date was Friday, February 20th. Bath & Body Works's dividend payout ratio (DPR) is 25.40%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on BBWI shares. Weiss Ratings reissued a "hold (c-)" rating on shares of Bath & Body Works in a research report on Monday, April 20th. Barclays lifted their price objective on Bath & Body Works from $20.00 to $21.00 and gave the company an "equal weight" rating in a research report on Monday, March 2nd. Telsey Advisory Group lifted their price objective on Bath & Body Works from $23.00 to $25.00 and gave the company a "market perform" rating in a research report on Thursday, March 5th. Jefferies Financial Group started coverage on Bath & Body Works in a research report on Wednesday, January 14th. They set a "hold" rating and a $24.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Bath & Body Works from $21.00 to $22.00 and gave the company a "hold" rating in a research report on Tuesday, March 3rd. Three analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $23.00.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.

Want to see what other hedge funds are holding BBWI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bath & Body Works, Inc. (NYSE:BBWI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.